Anders Gorst-Rasmussen
Overview
Explore the profile of Anders Gorst-Rasmussen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
566
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Broad versus narrow research questions in evidence synthesis: A parallel to (and plea for) estimands
Remiro-Azocar A, Gorst-Rasmussen A
Res Synth Methods
. 2024 Aug;
15(5):735-740.
PMID: 39118456
There has been a transition from broad to more specific research questions in the practice of network meta-analysis (NMA). Such convergence is also taking place in the context of individual...
2.
Lingvay I, Catarig A, Lawson J, Chubb B, Gorst-Rasmussen A, Evans L
Diabetes Ther
. 2022 Nov;
14(1):123-137.
PMID: 36434159
Introduction: To date, there have been few head-to-head comparisons between semaglutide once-weekly (OW) and short-acting meal-time insulin in participants with type 2 diabetes (T2D) treated with basal insulin and requiring...
3.
Gorst-Rasmussen A, Tarp-Johansen M
J Biopharm Stat
. 2022 Jun;
32(6):942-953.
PMID: 35653556
When dealing with missing data in clinical trials, it is often convenient to work under simplifying assumptions, such as missing at random (MAR), and follow up with sensitivity analyses to...
4.
Pratley R, Gorst-Rasmussen A
Diabetes Obes Metab
. 2022 Feb;
24(6):1180-1181.
PMID: 35129275
No abstract available.
5.
Gorst-Rasmussen A, Sturis J, Ekelund M
Diabetes Technol Ther
. 2021 Sep;
24(1):10-17.
PMID: 34524005
In the onset 5 trial, fast-acting insulin aspart (faster aspart) was noninferior to insulin aspart (IAsp) for change from baseline glycated hemoglobin at 16 weeks, when used in continuous subcutaneous...
6.
Pratley R, Catarig A, Lingvay I, Viljoen A, Paine A, Lawson J, et al.
Diabetes Obes Metab
. 2021 Jul;
23(11):2513-2520.
PMID: 34286894
Aim: To compare the effects of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg on HbA1c and body weight in patients with type 2 diabetes. Materials And Methods: A...
7.
Rose L, Kadowaki T, Pieber T, Buchholtz K, Ekelund M, Gorst-Rasmussen A, et al.
Diabetes Ther
. 2019 Apr;
10(3):1029-1041.
PMID: 30949906
Introduction: Insulin dosing based on carbohydrate counting is the gold standard for improving glycaemic control in type 1 diabetes (T1D). This post hoc analysis aimed to explore the efficacy and...
8.
Jakobsen M, Gorst-Rasmussen A, Eriksen H, Stegger J, Joensen A, Tjonneland A, et al.
PLoS One
. 2018 Aug;
13(8):e0202363.
PMID: 30133507
Background: The risk of coronary heart disease associated with intake of individual trans fatty acids (TFAs) is not clear. Adipose tissue content of TFAs is a biomarker of TFA intake...
9.
Andersen S, Larsen T, Gorst-Rasmussen A, Yavarian Y, Lip G, Bach F
Cerebrovasc Dis
. 2016 Oct;
43(1-2):17-24.
PMID: 27750251
Background: Nearly one in 5 patients with ischemic stroke will invariably experience a second stroke within 5 years. Stroke risk stratification schemes based solely on clinical variables perform only modestly...
10.
Vadmann H, Gorst-Rasmussen A, Hjortshoj S, Riahi S, Lip G, Larsen T
Europace
. 2016 Oct;
19(5):838-842.
PMID: 27738075
Aims: The aim of this study was to investigate whether there is a similar mortality and thrombo-embolic risk, after an atrial ablation procedure, compared with an atrial fibrillation (AF) procedure....